الفهرس 
VitiligoOnly 14 pages are availabe for public view
 |  | from | 162 |  |  |
| | | from | 162 | | |
Abstract
Vitiligo is an acquired pigmentary disorder of unknown etiology that
is clinically characterized by the development of white macules related to
the selective loss of melanocytes, affecting around 2% of world’s population.
Clinically, there are two types of vitiligo, localized vitiligo which can be
segmental or focal, and generalized vitiligo. The course of the disease is
unpredictable. The exact pathophysiology of vitiligo is not fully understood
and is likely multifactorial.
Interleukin-32 (IL-32) is a comparatively newly discovered cytokine
and studies on it are still in their early stages. Studies have shown that it is
produced by various cell types including T lymphocytes, natural killer cells,
monocytes, and epithelial cells. Of particular importance, IL-32 exhibits
numerous classical proinflammatory activities. It stimulates the production
of numerous cytokines including TNF-α, IL-1β, and IL-6. It also activates
proinflammatory signaling pathways such as mitogen-activated protein
kinase (MAPK)-p38, extracellular receptor kinases (ERK), and NF-kB. It
has four isoform variants, IL-32α, IL-32β, IL-32γ, and IL-32δ.Among all IL32 isoforms, IL-32α is the most abundant cDNA clone and has major
proinflammatory activity of IL-32. The proinflammatory role of IL-32 has
been well reported in several disorders including rheumatoid arthritis,
cancers, pulmonary tuberculosis, systematic lupus erythematosus, and also
in many skin disorders such as atopic dermatitis, hidradenitis suppurativa,
leishmaniasis, and psoriasis. However, the role of IL-32 in vitiligo was not
evaluated till now.
The aim of this study was to investigate the possible role of IL32 on
pathogenesis of vitiligo and correlate the estimated results with the clinical
aspects of vitiligo.
Fifty patients with active non segmental vitiligo from both sex and any
age and forty healthy volunteer controls were enrolled in the study. Patients
with VIDA +1 or more were included in the trial. For all participants, full
medical history, dermatological examination was performed. Also, CBC,
HbA1c and lipid profile will be done for all cases and controls. IL32 isoforms
(α and β) gene expression was measured by real time polymerase chain
reaction (RT-PCR) while IL32 serum level was measured by enzyme linked
immune sorbent assay (ELISA).